

NACCT 2021: Platform Presentation Schedule

New ID	Submission #	Platform Title	Presenting on	First Author
1	34	Exploration of the binding of hydroxocobalamin with sulfur containing compounds	Day 1 (Sat 10/16 1:00-3:00pm)	Patrick Ng
2	292	Glycolic Acid Exacerbates Analytical Performance of Lactate Assay	Day 1 (Sat 10/16 1:00-3:00pm)	Mahesheema Ali
3	314	The diagnostic value of D-Dimer in Australian snake envenoming (ASP-29)	Day 1 (Sat 10/16 1:00-3:00pm)	Geoffrey Isbister
4	289	Characterization of F(ab') ₂ and Fab Crotalidae Antivenom Single and Combination Therapy 2018-2020: Retrospective Analysis of the North American Snakebite Registry	Day 1 (Sat 10/16 1:00-3:00pm)	Christopher Pittoti
5	68	In vitro analysis of n-acetylcysteine (NAC) interference with the international normalized ratio (INR)	Day 1 (Sat 10/16 1:00-3:00pm)	Faisal Minhaj
6	317	New Insights on Acetaminophen Half-life Using Multisource Pharmacokinetic Data	Day 1 (Sat 10/16 1:00-3:00pm)	Grant Comstock
7	28	Evaluation of N-Acetylcysteine Dose for the Treatment of Massive Acetaminophen Ingestion	Day 1 (Sat 10/16 1:00-3:00pm)	Justin Lewis
8	201	Outbreak of Hepatitis of Unknown Etiology Associated with Bottled Alkaline Water Ingestion	Day 1 (Sat 10/16 1:00-3:00pm)	Colin Terriault
9	106	Validity and reliability of the Poisoning Severity Score in a pediatric poisoned population	Day 2 (Sun 10/17 1:30-2:30pm)	Elizabeth Canitrot
10	247	Pediatric Suicides Reported to the U.S. Poison Centers	Day 2 (Sun 10/17 1:30-2:30pm)	Jennifer Ross
11	133	Poison Center Patients: Reduced Mortality, Hospital Length of Stay, and Charges. Findings from a Linked Database	Day 2 (Sun 10/17 1:30-2:30pm)	Alvin Bronstein
12	211	Poison Center Utilization Decreases Emergency Healthcare Costs	Day 2 (Sun 10/17 1:30-2:30pm)	Amanda Korenoski
13	70	Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective case series	Day 3 (Mon 10/18 1:30-2:30pm)	Kevin Baumgartner

NACCT 2021: Platform Presentation Schedule

14	290	False Negatives in Urine Drug Screening to Inform Directed Expansion of Screening, Brief Intervention, and Referral to Treatment in Trauma Patients	Day 3 (Mon 10/18 1:30-2:30pm)	Stephanie Weiss
15	187	Characterization of Oxycodone Misuse using National Survey Data	Day 3 (Mon 10/18 1:30-2:30pm)	Saumitra Rege
16	160	Use of Benzodiazepines in Adolescents and Young Adults: Indications, Outcomes, and Harm-Reduction Strategies	Day 3 (Mon 10/18 1:30-2:30pm)	Michael Toci